1
|
Wang B, Wang Z, Li Y, Shang Z, Liu Z, Fan H, Zhan R, Xin T. TRIM56: a promising prognostic immune biomarker for glioma revealed by pan-cancer and single-cell analysis. Front Immunol 2024; 15:1327898. [PMID: 38348047 PMCID: PMC10859405 DOI: 10.3389/fimmu.2024.1327898] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2023] [Accepted: 01/12/2024] [Indexed: 02/15/2024] Open
Abstract
Tripartite-motif 56 (TRIM56) is a member of the TRIM family, and was shown to be an interferon-inducible E3 ubiquitin ligase that can be overexpressed upon stimulation with double-stranded DNA to regulate stimulator of interferon genes (STING) to produce type I interferon and thus mediate innate immune responses. Its role in tumors remains unclear. In this study, we investigated the relationship between the expression of the TRIM56 gene and its prognostic value in pan-cancer, identifying TRIM56 expression as an adverse prognostic factor in glioma patients. Therefore, glioma was selected as the primary focus of our investigation. We explored the differential expression of TRIM56 in various glioma subtypes and verified its role as an independent prognostic factor in gliomas. Our research revealed that TRIM56 is associated with malignant biological behaviors in gliomas, such as proliferation, migration, and invasion. Additionally, it can mediate M2 polarization of macrophages in gliomas. The results were validated in vitro and in vivo. Furthermore, we utilized single-cell analysis to investigate the impact of TRIM56 expression on cell communication between glioma cells and non-tumor cells. We constructed a multi-gene signature based on cell markers of tumor cells with high TRIM56 expression to enhance the prediction of cancer patient prognosis. In conclusion, our study demonstrates that TRIM56 serves as a reliable immune-related prognostic biomarker in glioma.
Collapse
Affiliation(s)
- Bingcheng Wang
- Department of Neurosurgery, Shandong Provincial Qianfoshan Hospital, Shandong University, Jinan, China
| | - Zhihai Wang
- Department of Neurosurgery, Shandong Provincial Qianfoshan Hospital, Shandong University, Jinan, China
| | - Yuchen Li
- Department of Neurosurgery, Shandong Provincial Qianfoshan Hospital, Shandong University, Jinan, China
| | - Zehan Shang
- Department of Neurosurgery, Shandong Provincial Qianfoshan Hospital, Shandong University, Jinan, China
| | - Zihao Liu
- Department of Neurosurgery, Shandong Provincial Hospital, Shandong University, Jinan, China
| | - Hao Fan
- Department of Neurosurgery, Shandong Provincial Qianfoshan Hospital, Shandong University, Jinan, China
| | - Rucai Zhan
- Department of Neurosurgery, Shandong Provincial Qianfoshan Hospital, Shandong University, Jinan, China
| | - Tao Xin
- Department of Neurosurgery, Shandong Provincial Qianfoshan Hospital, Shandong University, Jinan, China
- Department of Neurosurgery, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Shandong Medicine and Health Key Laboratory of Neurosurgery, Jinan, China
- Department of Neurosurgery, Jiangxi Provincial People’s Hospital Affiliated to Nanchang University, Nanchang, China
- Medical Science and Technology Innovation Center, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China
| |
Collapse
|
2
|
Luo J, Lu C, Chen Y, Wu X, Zhu C, Cui W, Yu S, Li N, Pan Y, Zhao W, Yang Q, Yang X. Nuclear translocation of cGAS orchestrates VEGF-A-mediated angiogenesis. Cell Rep 2023; 42:112328. [PMID: 37027305 DOI: 10.1016/j.celrep.2023.112328] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2022] [Revised: 12/20/2022] [Accepted: 03/17/2023] [Indexed: 04/08/2023] Open
Abstract
Cyclic GMP-AMP synthase (cGAS) senses cytosolic incoming DNA and consequently activates stimulator of interferon response cGAMP interactor 1 (STING) to mount immune response. Here, we show nuclear cGAS could regulate VEGF-A-mediated angiogenesis in an immune-independent manner. We found VEGF-A stimulation induces cGAS nuclear translocation via importin-β pathway. Moreover, nuclear cGAS subsequently regulates miR-212-5p-ARPC3 cascade to modulate VEGF-A-mediated angiogenesis through affecting cytoskeletal dynamics and VEGFR2 trafficking from trans-Golgi network (TGN) to plasma membrane via a regulatory feedback loop. In contrast, cGAS deficiency remarkably impairs VEGF-A-mediated angiogenesis in vivo and in vitro. Furthermore, we found strong association between the expression of nuclear cGAS and VEGF-A, and the malignancy and prognosis in malignant glioma, suggesting that nuclear cGAS might play important roles in human pathology. Collectively, our findings illustrated the function of cGAS in angiogenesis other than immune surveillance, which might be a potential therapeutic target for pathological angiogenesis-related diseases.
Collapse
Affiliation(s)
- Juanjuan Luo
- Shantou University Medical College, Shantou, Guangdong 515041, China
| | - Chunjiao Lu
- Shantou University Medical College, Shantou, Guangdong 515041, China
| | - Yang Chen
- Shantou University Medical College, Shantou, Guangdong 515041, China
| | - Xuewei Wu
- Shantou University Medical College, Shantou, Guangdong 515041, China
| | - Chenchen Zhu
- Shantou University Medical College, Shantou, Guangdong 515041, China
| | - Wei Cui
- College of Life Science and Biopharmaceutical of Shenyang Pharmaceutical University, Shenyang, Liaoning 110016, China
| | - Shicang Yu
- Southwest Hospital, Third Military Medical University, Chongqing 400038, China
| | - Ningning Li
- The Seventh Affiliated Hospital of Sun Yat-sen University, Shenzhen, Guangdong 518107, China
| | - Yihang Pan
- The Seventh Affiliated Hospital of Sun Yat-sen University, Shenzhen, Guangdong 518107, China
| | - Weijiang Zhao
- Wuxi School of Medicine, Jiangnan University, Wuxi, Jiangsu 214122, China
| | - Qingkai Yang
- Institute of Cancer Stem Cell, Dalian Medical University, Dalian, Liaoning 116044, China.
| | - Xiaojun Yang
- Shantou University Medical College, Shantou, Guangdong 515041, China.
| |
Collapse
|
3
|
Burghardt I, Schroeder JJ, Weiss T, Gramatzki D, Weller M. A tumor-promoting role for soluble TβRIII in glioblastoma. Mol Cell Biochem 2021; 476:2963-2973. [PMID: 33772427 PMCID: PMC8263459 DOI: 10.1007/s11010-021-04128-y] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2020] [Accepted: 03/04/2021] [Indexed: 12/21/2022]
Abstract
Purpose Members of the transforming growth factor (TGF)-β superfamily play a key role in the regulation of the malignant phenotype of glioblastoma by promoting invasiveness, angiogenesis, immunosuppression, and maintaining stem cell-like properties. Betaglycan, a TGF-β coreceptor also known as TGF-β receptor III (TβRIII), interacts with members of the TGF-β superfamily and acts as membrane-associated or shed molecule. Shed, soluble TβRIII (sTβRIII) is produced upon ectodomain cleavage of the membrane-bound form. Elucidating the role of TβRIII may improve our understanding of TGF-β pathway activity in glioblastoma Methods Protein levels of TβRIII were determined by immunohistochemical analyses and ex vivo single-cell gene expression profiling of glioblastoma tissue respectively. In vitro, TβRIII levels were assessed investigating long-term glioma cell lines (LTCs), cultured human brain-derived microvascular endothelial cells (hCMECs), glioblastoma-derived microvascular endothelial cells, and glioma-initiating cell lines (GICs). The impact of TβRIII on TGF-β signaling was investigated, and results were validated in a xenograft mouse glioma model Results Immunohistochemistry and ex vivo single-cell gene expression profiling of glioblastoma tissue showed that TβRIII was expressed in the tumor tissue, predominantly in the vascular compartment. We confirmed this pattern of TβRIII expression in vitro. Specifically, we detected sTβRIII in glioblastoma-derived microvascular endothelial cells. STβRIII facilitated TGF-β-induced Smad2 phosphorylation in vitro and overexpression of sTβRIII in a xenograft mouse glioma model led to increased levels of Smad2 phosphorylation, increased tumor volume, and decreased survival Conclusions These data shed light on the potential tumor-promoting role of extracellular shed TβRIII which may be released by glioblastoma endothelium with high sTβRIII levels. Supplementary Information The online version contains supplementary material available at 10.1007/s11010-021-04128-y.
Collapse
Affiliation(s)
- Isabel Burghardt
- Laboratory of Molecular Neuro-Oncology, Department of Neurology & Brain Tumor Center, University Hospital and University of Zurich, Frauenklinikstrasse 26, 8091, Zurich, Switzerland
| | - Judith Johanna Schroeder
- Laboratory of Molecular Neuro-Oncology, Department of Neurology & Brain Tumor Center, University Hospital and University of Zurich, Frauenklinikstrasse 26, 8091, Zurich, Switzerland
| | - Tobias Weiss
- Laboratory of Molecular Neuro-Oncology, Department of Neurology & Brain Tumor Center, University Hospital and University of Zurich, Frauenklinikstrasse 26, 8091, Zurich, Switzerland
| | - Dorothee Gramatzki
- Laboratory of Molecular Neuro-Oncology, Department of Neurology & Brain Tumor Center, University Hospital and University of Zurich, Frauenklinikstrasse 26, 8091, Zurich, Switzerland
| | - Michael Weller
- Laboratory of Molecular Neuro-Oncology, Department of Neurology & Brain Tumor Center, University Hospital and University of Zurich, Frauenklinikstrasse 26, 8091, Zurich, Switzerland.
| |
Collapse
|
5
|
Osterberg N, Ferrara N, Vacher J, Gaedicke S, Niedermann G, Weyerbrock A, Doostkam S, Schaefer HE, Plate KH, Machein MR. Decrease of VEGF-A in myeloid cells attenuates glioma progression and prolongs survival in an experimental glioma model. Neuro Oncol 2016; 18:939-49. [PMID: 26951383 DOI: 10.1093/neuonc/now005] [Citation(s) in RCA: 36] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/09/2015] [Accepted: 01/11/2016] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND Glioblastomas are highly vascularized tumors with a prominent infiltration of macrophages/microglia whose role in promoting glioma growth, invasion, and angiogenesis has not been fully elucidated. METHODS The contribution of myeloid-derived vascular endothelial growth factor (VEGF) to glioma growth was analyzed in vivo in a syngeneic intracranial GL261 glioma model using a Cre/loxP system to knock out the expression of VEGF-A in CD11b + myeloid cells. Changes in angiogenesis-related gene expression profile were analyzed in mutant bone marrow-derived (BMD) macrophages in vitro. Furthermore, we studied the influence of macrophages on GL261 growth, invasiveness, and protein expression profile of angiogenic molecules as well as the paracrine effect of mutant macrophages on angiogenesis in vitro. RESULTS Myeloid cell-restricted VEGF-A deficiency leads to a growth delay of intracranial tumors and prolonged survival. The tumor vasculature in mutant mice was more regular, with increased pericyte coverage. Expression analysis revealed significant downregulation of VEGF-A and slight upregulation of TGFβ-1 in BMD macrophages from mutant mice. Endothelial tube formation was significantly decreased by conditioned media from mutant macrophages. The expression of angiogenesis-related proteins in GL261 glioma cells in co-culture experiments either with wild-type or mutant macrophages remained unchanged, indicating that effects observed in vivo are due to myeloid-derived VEGF-A deficiency. CONCLUSIONS Our results highlight the importance of VEGF derived from tumor-infiltrating myeloid cells for initiating vascularization in gliomas. The combination of antiangiogenic agents with myeloid cell-targeting strategies might provide a new therapeutic approach for glioblastoma patients.
Collapse
Affiliation(s)
- Nadja Osterberg
- Department of Neurosurgery, Freiburg University Medical School, Freiburg, Germany (N.O., A.W., M.R.M.); Department of Pathology, University of California San Diego, San Diego, California (N.F.); Department of Medicine, Institut de Recherches Cliniques de Montréal, Université de Montréal, Quebec, Canada (J.V.); Department of Radiation Oncology, University Hospital Freiburg, Germany (S.G., G.N.); Department of Neuropathology, Freiburg University Medical School, Freiburg, Germany (S.D.); Department of Pathology, Freiburg University Medical School, Freiburg, Germany (H.-E.S.); Institute of Neurology (Edinger Institute), Frankfurt University Medical School, Frankfurt, Germany (K.H.P)
| | - Napoleone Ferrara
- Department of Neurosurgery, Freiburg University Medical School, Freiburg, Germany (N.O., A.W., M.R.M.); Department of Pathology, University of California San Diego, San Diego, California (N.F.); Department of Medicine, Institut de Recherches Cliniques de Montréal, Université de Montréal, Quebec, Canada (J.V.); Department of Radiation Oncology, University Hospital Freiburg, Germany (S.G., G.N.); Department of Neuropathology, Freiburg University Medical School, Freiburg, Germany (S.D.); Department of Pathology, Freiburg University Medical School, Freiburg, Germany (H.-E.S.); Institute of Neurology (Edinger Institute), Frankfurt University Medical School, Frankfurt, Germany (K.H.P)
| | - Jean Vacher
- Department of Neurosurgery, Freiburg University Medical School, Freiburg, Germany (N.O., A.W., M.R.M.); Department of Pathology, University of California San Diego, San Diego, California (N.F.); Department of Medicine, Institut de Recherches Cliniques de Montréal, Université de Montréal, Quebec, Canada (J.V.); Department of Radiation Oncology, University Hospital Freiburg, Germany (S.G., G.N.); Department of Neuropathology, Freiburg University Medical School, Freiburg, Germany (S.D.); Department of Pathology, Freiburg University Medical School, Freiburg, Germany (H.-E.S.); Institute of Neurology (Edinger Institute), Frankfurt University Medical School, Frankfurt, Germany (K.H.P)
| | - Simone Gaedicke
- Department of Neurosurgery, Freiburg University Medical School, Freiburg, Germany (N.O., A.W., M.R.M.); Department of Pathology, University of California San Diego, San Diego, California (N.F.); Department of Medicine, Institut de Recherches Cliniques de Montréal, Université de Montréal, Quebec, Canada (J.V.); Department of Radiation Oncology, University Hospital Freiburg, Germany (S.G., G.N.); Department of Neuropathology, Freiburg University Medical School, Freiburg, Germany (S.D.); Department of Pathology, Freiburg University Medical School, Freiburg, Germany (H.-E.S.); Institute of Neurology (Edinger Institute), Frankfurt University Medical School, Frankfurt, Germany (K.H.P)
| | - Gabriele Niedermann
- Department of Neurosurgery, Freiburg University Medical School, Freiburg, Germany (N.O., A.W., M.R.M.); Department of Pathology, University of California San Diego, San Diego, California (N.F.); Department of Medicine, Institut de Recherches Cliniques de Montréal, Université de Montréal, Quebec, Canada (J.V.); Department of Radiation Oncology, University Hospital Freiburg, Germany (S.G., G.N.); Department of Neuropathology, Freiburg University Medical School, Freiburg, Germany (S.D.); Department of Pathology, Freiburg University Medical School, Freiburg, Germany (H.-E.S.); Institute of Neurology (Edinger Institute), Frankfurt University Medical School, Frankfurt, Germany (K.H.P)
| | - Astrid Weyerbrock
- Department of Neurosurgery, Freiburg University Medical School, Freiburg, Germany (N.O., A.W., M.R.M.); Department of Pathology, University of California San Diego, San Diego, California (N.F.); Department of Medicine, Institut de Recherches Cliniques de Montréal, Université de Montréal, Quebec, Canada (J.V.); Department of Radiation Oncology, University Hospital Freiburg, Germany (S.G., G.N.); Department of Neuropathology, Freiburg University Medical School, Freiburg, Germany (S.D.); Department of Pathology, Freiburg University Medical School, Freiburg, Germany (H.-E.S.); Institute of Neurology (Edinger Institute), Frankfurt University Medical School, Frankfurt, Germany (K.H.P)
| | - Soroush Doostkam
- Department of Neurosurgery, Freiburg University Medical School, Freiburg, Germany (N.O., A.W., M.R.M.); Department of Pathology, University of California San Diego, San Diego, California (N.F.); Department of Medicine, Institut de Recherches Cliniques de Montréal, Université de Montréal, Quebec, Canada (J.V.); Department of Radiation Oncology, University Hospital Freiburg, Germany (S.G., G.N.); Department of Neuropathology, Freiburg University Medical School, Freiburg, Germany (S.D.); Department of Pathology, Freiburg University Medical School, Freiburg, Germany (H.-E.S.); Institute of Neurology (Edinger Institute), Frankfurt University Medical School, Frankfurt, Germany (K.H.P)
| | - Hans-Eckart Schaefer
- Department of Neurosurgery, Freiburg University Medical School, Freiburg, Germany (N.O., A.W., M.R.M.); Department of Pathology, University of California San Diego, San Diego, California (N.F.); Department of Medicine, Institut de Recherches Cliniques de Montréal, Université de Montréal, Quebec, Canada (J.V.); Department of Radiation Oncology, University Hospital Freiburg, Germany (S.G., G.N.); Department of Neuropathology, Freiburg University Medical School, Freiburg, Germany (S.D.); Department of Pathology, Freiburg University Medical School, Freiburg, Germany (H.-E.S.); Institute of Neurology (Edinger Institute), Frankfurt University Medical School, Frankfurt, Germany (K.H.P)
| | - Karl H Plate
- Department of Neurosurgery, Freiburg University Medical School, Freiburg, Germany (N.O., A.W., M.R.M.); Department of Pathology, University of California San Diego, San Diego, California (N.F.); Department of Medicine, Institut de Recherches Cliniques de Montréal, Université de Montréal, Quebec, Canada (J.V.); Department of Radiation Oncology, University Hospital Freiburg, Germany (S.G., G.N.); Department of Neuropathology, Freiburg University Medical School, Freiburg, Germany (S.D.); Department of Pathology, Freiburg University Medical School, Freiburg, Germany (H.-E.S.); Institute of Neurology (Edinger Institute), Frankfurt University Medical School, Frankfurt, Germany (K.H.P)
| | - Marcia Regina Machein
- Department of Neurosurgery, Freiburg University Medical School, Freiburg, Germany (N.O., A.W., M.R.M.); Department of Pathology, University of California San Diego, San Diego, California (N.F.); Department of Medicine, Institut de Recherches Cliniques de Montréal, Université de Montréal, Quebec, Canada (J.V.); Department of Radiation Oncology, University Hospital Freiburg, Germany (S.G., G.N.); Department of Neuropathology, Freiburg University Medical School, Freiburg, Germany (S.D.); Department of Pathology, Freiburg University Medical School, Freiburg, Germany (H.-E.S.); Institute of Neurology (Edinger Institute), Frankfurt University Medical School, Frankfurt, Germany (K.H.P)
| |
Collapse
|